Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering Rebetol Costs $1,650 Per Month, 3% Less Than Combo Rebetron

Executive Summary

Schering-Plough's Rebetol is 97% of the cost for its hepatitis C combination product Rebetron that includes Rebetol and Intron-A.

You may also be interested in...



Ribavirin ANDAs Await ICN Petition; FDA Generic Rule Takes Effect

The delay in approval for generic versions of Schering-Plough's Rebetol (ribavirin) illustrates one limitation of FDA's revised Waxman/Hatch regulations

Ribavirin ANDAs Await ICN Petition; FDA Generic Rule Takes Effect

The delay in approval for generic versions of Schering-Plough's Rebetol (ribavirin) illustrates one limitation of FDA's revised Waxman/Hatch regulations

PEG-Intron Access Program Requires ID Number, Designed To Ensure Supply

Schering-Plough is implementing a prescription tracking program for PEG-Intron to ensure that existing patients will have adequate supply of peginterferon alfa-2b

Related Content

UsernamePublicRestriction

Register

PS038681

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel